KIRTAMSY

Serial Number 79373551
Registration 7546739
700

Registration Progress

Application Filed
Apr 12, 2023
Under Examination
Approved for Publication
Aug 13, 2024
Published for Opposition
Aug 13, 2024
Registered
Oct 29, 2024

Basic Information

Serial Number
79373551
Registration Number
7546739
Filing Date
April 12, 2023
Registration Date
October 29, 2024
Published for Opposition
August 13, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Oct 29, 2024
Registration
Registered
Classes
005

Rights Holder

Innate Pharma

33
Address
117 avenue de Luminy
F-13009 Marseille
FR

Ownership History

Innate Pharma

Original Applicant
33
FR

Innate Pharma

Owner at Publication
33
FR

Innate Pharma

Original Registrant
33
FR

Legal Representation

Attorney
Mitchell E. Radin
USPTO Deadlines 1 active 1 overdue
Deadline Type Event Code Deadline Date Days Until Priority Extension Available
OPPOSITION
Notice of Publication
NPUB Sep 12, 2024 298 days overdue Medium Until Oct 12, 2024

Application History

18 events
Date Code Type Description
Oct 29, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 29, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER
Aug 13, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 13, 2024 PUBO A PUBLISHED FOR OPPOSITION
Jul 24, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 9, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 9, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 9, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 9, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 14, 2024 RFNT P REFUSAL PROCESSED BY IB
Jan 25, 2024 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 25, 2024 RFRR P REFUSAL PROCESSED BY MPU
Jan 10, 2024 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 9, 2024 CNRT R NON-FINAL ACTION WRITTEN
Jan 9, 2024 DOCK D ASSIGNED TO EXAMINER
Jul 11, 2023 MAFR O APPLICATION FILING RECEIPT MAILED
Jul 7, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 6, 2023 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of cancer, immunoproliferative disorders, inflammatory disorders and autoimmune disorders, hematological malignancies, lymphomas, T-cell lymphomas, cutaneous T cell lymphomas, Sezary Syndrome and Mycosis fungoides.

Classification

International Classes
005